1 / 1

AAA

AAA. Primary outcome (coronary event, stroke, revascularization) similar in aspirin and placebo arms (HR = 1.03, 95% CI 0.84-1.27) Mortality, stroke, MI rates similar Major bleeding requiring hospital admission higher in aspirin arm (2.0% vs. 1.2%, p = NS). (p = NS). (p = NS).

benito
Télécharger la présentation

AAA

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. AAA Primary outcome (coronary event, stroke, revascularization) similar in aspirin and placebo arms (HR = 1.03, 95% CI 0.84-1.27) Mortality, stroke, MI rates similar Major bleeding requiring hospital admission higher in aspirin arm (2.0% vs. 1.2%, p = NS) (p = NS) (p = NS) Trial design: Patients with no known CV disease, with an ABI ≤0.95, were randomized to enteric coated aspirin 100 mg daily or placebo. Patient follow-up was a mean of 8.2 years. Results 30 30 20 20 Conclusions % % 11.1 10.5 10.8 10.5 • In patients without known CAD, with an ABI ≤0.95, no benefit noted with aspirin for primary prevention of vascular events; aspirin was associated with higher risk of bleeding • Data on primary prevention of CAD with aspirin are conflicting - some studies (PHS) show a benefit, others (WHS, JPAD, AAA) show negative results 10 10 0 0 Primary endpoint All-cause mortality Aspirin (n = 1,675) Placebo (n = 1,675) Presented by Dr. Gary Fowkes at ESC 2009

More Related